MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech, expanding their global strategic partnership

May 26, 2024

https://www.prnewswire.com/news-releases/medilink-therapeutics-announces-a-multi-target-tmalin-adc-technology-platform-license-agreement-with-biontech-expanding-their-global-strategic-partnership-302155699.html

SUZHOU, China, May 26, 2024 /PRNewswire/ — MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink”), a clinical-stage biotech company, today announces a new strategic collaboration with BioNTech SE (Nasdaq: BNTX, “BioNTech”), a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, under which BioNTech will receive an exclusive option to an exclusive global license to apply MediLink’s TMALIN® antibody-drug conjugate (ADC) platform, for several novel targets chosen by BioNTech.

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.